Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan and Alpha-Lipoic Acid for BP in OSA
NCT04021550Phase 1Withdrawn
- Sponsor
- University of British Columbia
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of telmisartan in obstructive sleep apnea (OSA) (2 arms), sponsored by University of British Columbia. Primary endpoint: Change in 24-hour blood pressure at 6 weeks. Planned start May 2023; status: withdrawn.
02
Drugs
telmisartan
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04021550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021550.